Fesoterodine Fumarate Patent Expiration
Fesoterodine Fumarate is Used for treating overactive bladder symptoms such as urge urinary incontinence, urgency, and frequency. It was first introduced by Pfizer Inc
Fesoterodine Fumarate Patents
Given below is the list of patents protecting Fesoterodine Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Toviaz |
US7807715 (Pediatric) | Pharmaceutical compositions comprising fesoterodine | Dec 07, 2027 | Pfizer |
| Toviaz |
US8088398 (Pediatric) | Pharmaceutical compositions comprising fesoterodine | Dec 07, 2027 | Pfizer |
| Toviaz |
US8501723 (Pediatric) | Pharmaceutical compositions comprising fesoterodine | Dec 07, 2027 | Pfizer |
| Toviaz | US7807715 | Pharmaceutical compositions comprising fesoterodine | Jun 07, 2027 | Pfizer |
| Toviaz | US8088398 | Pharmaceutical compositions comprising fesoterodine | Jun 07, 2027 | Pfizer |
| Toviaz | US8501723 | Pharmaceutical compositions comprising fesoterodine | Jun 07, 2027 | Pfizer |
| Toviaz |
US6858650 (Pediatric) | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jan 03, 2023
(Expired) | Pfizer |
| Toviaz | US6858650 | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul 03, 2022
(Expired) | Pfizer |
| Toviaz | US7384980 | Derivatives of 3,3-diphenylpropylamines |
May 11, 2019
(Expired) | Pfizer |
| Toviaz | US7855230 | Derivatives of 3,3-diphenylpropylamines |
May 11, 2019
(Expired) | Pfizer |
| Toviaz | US7985772 | Derivatives of 3,3-diphenylpropylamines |
May 11, 2019
(Expired) | Pfizer |
| Toviaz | US8338478 | Derivatives of 3,3-diphenylpropylamines |
May 11, 2019
(Expired) | Pfizer |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Fesoterodine Fumarate's patents.
Latest Legal Activities on Fesoterodine Fumarate's Patents
Given below is the list recent legal activities going on the following patents of Fesoterodine Fumarate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical
| 28 Aug, 2023 | US7985772(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Jun, 2023 | US8088398 |
| Maintenance Fee Reminder Mailed Critical
| 13 Mar, 2023 | US7985772(Litigated) |
| Expire Patent Critical
| 23 Jan, 2023 | US7855230(Litigated) |
| Maintenance Fee Reminder Mailed Critical
| 08 Aug, 2022 | US7855230(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Mar, 2022 | US7807715 |
| Expire Patent Critical
| 01 Feb, 2021 | US8338478(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Jan, 2021 | US8501723 |
| Maintenance Fee Reminder Mailed Critical
| 17 Aug, 2020 | US8338478(Litigated) |
| Expire Patent Critical
| 13 Jul, 2020 | US7384980(Litigated) |
Fesoterodine Fumarate's Family Patents
